Scalable fabrication of size-controlled chitosan nanoparticles for oral delivery of insulin

He, Zhiyu; Santos, José Lúıs; Tian, Houkuan; Huang, Hui; Hu, Yizong; Liu, Lixin; Leong, Kam W.; Chen, Yongming; Mao, Hai‐Quan

doi:10.1016/j.biomaterials.2017.03.028

Cited by 208 publications

(114 citation statements)

References 53 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…This heterogeneity can be exacerbated by scaling up from small scale bulk mixing conditions found in a laboratory to larger size volumes, especially as mixing environments vary with different types of processing equipment. To help alleviate these concerns, increasing attention in the nanomedicine field has turned to continuous manufacture processes such as microfluidic mixing and extrusion techniques that can be more easily scaled in a homogenous and robust manner . Similarly, to minimize variability in patient outcomes, homogeneity in nanomedicine properties is critical and may necessitate improvements to both separation and characterization methods to ensure precision.…”

Section: Discussionmentioning

confidence: 99%

Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery

2019

View full text Add to dashboard Cite

Nucleic acids are a promising type of therapeutic for the treatment of a wide range of conditions, including cancer, but they also pose many delivery challenges. For efficient and safe delivery to cancer cells, nucleic acids must generally be packaged into a vehicle, such as a nanoparticle, that will allow them to be taken up by the target cells and then released in the appropriate cellular compartment to function. As with other types of therapeutics, delivery vehicles for nucleic acids must also be designed to avoid unwanted side effects; thus, the ability of such carriers to target their cargo to cancer cells is crucial. Classes of nucleic acids, hurdles that must be overcome for effective intracellular delivery, types of nonviral nanomaterials used as delivery vehicles, and the different strategies that can be employed to target nucleic acid delivery specifically to tumor cells are discussed. Additonally, nanoparticle designs that facilitate multiplexed delivery of combinations of nucleic acids are reviewed.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery

2019

View full text Add to dashboard Cite

show abstract

“…45 Also, He et al worked in the scalable fabrication of size-controlled chitosan nanoparticles for oral delivery of insulin. 46 A comparison of the techniques of emulsion diffusion, solvent displacement, and double emulsion to prepare doxorubicin-loaded nanoparticles has also been reported in the literature. 47 Sah et al provided the fundamentals into emulsion solvent evaporation/extraction, salting-out, nanoprecipitation, membrane emulsication, microuidic technology, and ow focusing.…”

Section: Introductionmentioning

confidence: 99%

PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In a MIVM, insulin-loaded nanoparticles were engineered by infusing aqueous solutions of chitosan, tripolyphosphate and insulin with a production rate of ca. 122 g/day, when the flow rate was 50 mL/min (Figure 10f) [139]. The insulin-loaded chitosan nanoparticles showed a smaller average particle size (down to 45 nm), narrower size distribution and higher encapsulation efficiency (up to 90%), compared with the counterparts prepared by the bulk-mixing method (Figure 10g).…”

Section: Polymeric Nanoparticlesmentioning

confidence: 96%

Current developments and applications of microfluidic technology toward clinical translation of nanomedicines

Liu

Zhang

Fontana

et al. 2018

Advanced Drug Delivery Reviews

177

127

View full text Add to dashboard Cite

Nanoparticulate drug delivery systems hold great potential for the therapy of many diseases, especially cancer. However, the translation of nanoparticulate drug delivery systems from academic research to industrial and clinical practice has been slow. This slow translation can be ascribed to the high batch-to-batch variations and insufficient production rate of the conventional preparation methods, and the lack of technologies for rapid screening of nanoparticulate drug delivery systems with high correlation to the in vivo tests. These issues can be addressed by the microfluidic technologies. For example, microfluidics can not only produce nanoparticles in a well-controlled, reproducible, and high-throughput manner, but also create 3D environments with continuous flow to mimic the physiological and/or pathological processes. This review provides an overview of the microfluidic devices developed to prepare nanoparticulate drug delivery systems, including drug nanosuspensions, polymer nanoparticles, polyplexes, structured nanoparticles and theranostic nanoparticles. We also highlight the recent advances of microfluidic systems in fabricating the increasingly realistic models of the in vivo milieu for rapid screening of nanoparticles. Overall, the microfluidic technologies offer a promise approach to accelerate the clinical translation of nanoparticulate drug delivery systems.

show abstract

Scalable fabrication of size-controlled chitosan nanoparticles for oral delivery of insulin

Cited by 208 publications

References 53 publications

Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery

Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery

PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters

Current developments and applications of microfluidic technology toward clinical translation of nanomedicines

Contact Info

Product

Resources

About